Editorial: A world without flu? It’s possible
Nasty viruses that deliver gruesome death (Ebola) or cause horrific birth defects (Zika) understandably get the big headlines when they flare up. The outbreaks are followed by calls for action and furious scrambling by scientists to come up with a cure. And while that’s reasonable, it contrasts sharply with the oddly ho-hum attitude humans seem to have developed toward a deadlier viral killer — influenza — that shows up every year without fail to inflict widespread sickness and death. In a typical year, influenza-related illnesses claim the lives of 290,000 to 650,000 humans, most of them old or infirm.
The 2017-2018 flu season is shaping up to be one of the deadliest in recent history. The illness hit hard and early, killing an unusually high number of young and healthy people (30 children had died in the U.S. by mid-January), causing a shortage of antiviral medicine and prompting some overwhelmed hospitals to take drastic action, such as treating sick people in parking lots. The dominant strain this go-around, influenza A (H3N2), is unusually lethal, and the vaccine prepared for this season is particularly ineffective at preventing people from getting sick. These developments signal that it’s time for the nation to focus its efforts on developing universal flu vaccines that provide long-term protection from all strains.
For the record:
12:30 PM, Jan. 26, 2018An earlier version of this editorial said the Spanish flu of 1918 killed as much as one-third of the world’s population. As much as one-third of the global population was infected, but the death toll (between 20 million and 50 million people) amounted to less than 3% of the world’s 1.8 billion inhabitants.
There’s hope for improved if not quite universal vaccines as soon as five years from now.
The current method of developing seasonal flu shots is little more than guesswork. Scientists do the best they can to predict the strain that will be circulating the following year. Even at their most effective, these short-term vaccines rarely confer half the population with protection from infection. We can do better. It may sound like fantasy, but universal vaccines are well within the realm of possibility.
Last week, a UCLA-based team of researchers reported in the journal Science that they have found a novel way to protect mice and ferrets from some influenza strains that may well be applicable to other viruses and to humans. Influenza is able to make people ill because of its ability to hide from the immune system’s initial defenses. The UCLA team found it could disable this ability so the virus could be killed off before it can do harm.
Granted, before a cure can be declared, the data must be replicated and human trials must be conducted successfully — a set of hurdles that won’t be cleared for years, if ever. Still, the UCLA results are a tremendously promising step that has scientists and epidemiologists hopeful it could lead to a vaccine that offers full protection from deadly flu in the coming decades.
There’s also hope for improved if not quite universal vaccines as soon as five years from now. That prospect is why Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, has made it an agency priority to push for better vaccines. Another motivating factor: the risk of a flu pandemic that reaches Stephen King-like proportions. It’s been a century since the Spanish Flu infected as much as a third of the global population, and epidemiologists say humanity is due for another “Big One.”
Because pandemics happen when influenza viruses make huge mutations, rather than small shifts, seasonal flu shots would offer little to no protection. Let’s not wait until then to stop treating the flu like a familiar, if troublesome, annual houseguest. Finding a better way to fight this serial killer needs to be given at least as much urgency as attacking the next sexy virus that pops up in the news.
A cure for the common opinion
Get thought-provoking perspectives with our weekly newsletter.
You may occasionally receive promotional content from the Los Angeles Times.